Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Q2 Beats; Management Maps Out Phase 3 GS-7977 Plans
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $56.00.
Analyst, Alan Carr, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Alan Carr, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
